Lipocine
LPCN
33 hedge funds and large institutions have $11.5M invested in Lipocine in 2020 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 3 reducing their positions, and 6 closing their positions.
3,043% more call options, than puts
Call options by funds: $723K | Put options by funds: $23K
233% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 3
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
14% more capital invested
Capital invested by funds: $10.1M → $11.5M (+$1.41M)
14% more funds holding
Funds holding: 29 → 33 (+4)
0.12% more ownership
Funds ownership: 0.64% → 0.76% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$896K |
| 2 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$490K |
| 3 |
VF
Virtu Financial
New York
|
+$294K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$213K |
| 5 |
AC
Aristides Capital
Louisville,
Kentucky
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$625K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$264K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$75K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$37.6K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37K |
LPCN Hedge Fund Activity: Q4 2020 in Review
33 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q4 2020, worth a combined $11.5M — up 14% from $10.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LPCN positions and 6 closed out — a net gain of 4 holders — while 10 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $896K. The largest seller was Sabby Management, exiting entirely with an estimated $625K sold.
- 33 institutional investors held Lipocine (LPCN) as of Q4 2020, up from 29 in Q3 2020.
- Funds reported $11.5M of Lipocine stock for Q4 2020, up 14% quarter-over-quarter.
- 10 funds opened new Lipocine positions in Q4 2020 and 6 closed out, a net change of +4 holders.
- The largest Lipocine buyer in Q4 2020 was Vanguard Group, an estimated $896K added.
- The largest Lipocine seller in Q4 2020 was Sabby Management, an estimated $625K sold.
Based on aggregated 13F filings for Q4 2020.